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Background
Guillain-Barre Syndrome (GBS) is an acute inflammatory polyneuropathy, most 
commonly characterized by rapidly progressive, essentially symmetric weakness and 
areflexia(1). Since the marked decline in poliomyelitis incidence, GBS has become 
the most common cause of acute flaccid paralysis in children. There is no distinctive 
test to confirm the diagnosis of GBS, and there is considerable heterogeneity in the 
presentation and clinical course. Further, variants of the disease have emerged to 
make GBS a true syndrome rather than a specific disease.
Epidemiology
GBS, reported worldwide, involves both genders and all ages. The incidence of 
typical GBS has been reported to be between 0.6 and 4 cases per 100000 population 
per year across the world (2), the incidence for children under 15 years being similar 
to that of adults. In a report from the northwest of Iran, the incidence rate was 2.27 
per 100000 population of ≤ 15 years children (3). While the syndrome occurs at 
all ages, it predominantly affects children aged 1- 5 years (4-5). Although there 
are documented cases of GBS in newborns, the syndrome is rare in infants (6). 
There is a slight male predominance with male to female ratio of 1.5:1. Most cases 
of the syndrome occur sporadically; however occurrence of epidemic clusters of 
GBS has also been described. The motor axonal form of GBS occurs in epidemics 
during summer in northern China and predominantly affects children probably by 
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Abstract
Objective 
The Guillain-Barre syndrome (GBS) is characterized by the acute onset of rapidly 
progressive, symmetric muscle weakness with absent or decreased deep tendon 
reflexes. GBS is the most common cause of acute flaccid paralysis in childhood, 
with an incidence of 0.6-4 per 100 000 population per year. The clinical features 
are distinct and obtaining patient’s history and conducting an examination 
generally lead to the diagnosis that can be confirmed by supportive laboratory 
tests and electrodiagnostic studies. The major considerations in differential 
diagnosis include transverse myelities, toxic neuropathy, tick paralysis, infantile 
butolism and myasthenia gravis. Although most children with GBS have a 
relatively benign clinical course, some become quite ill and require intubation 
with intensive care monitoring .Immunomodulating treatment should be used 
for any child who loses the ability to walk.
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campylobacter jejuni infection (7). An unexpectedly high 
incidence of GBS was reported in 2003 in the northwest 
of Iran (3). Serological evidence of recent campylobacter 
jejuni infection was found in about half of children with 
GBS in the same region (8).
Approximately half to two thirds of patients are reported 
to have a preceding illness, most commonly upper 
respiratory tract infection or gastroenteritis, within 4 
weeks period before the onset of the GBS symptoms. 
Numerous case reports and descriptions of large series 
have implicated a plethora of different infections and 
other events as possible antecedents of GBS. Evidence 
from case-control studies has suggested the role of 
campylobacter jejuni, cytomegalovirus, Epstein-Barr 
virus, Mycoplasma pneumoniae, rabies vaccine and 
“swine flue” vaccine (9,10).
Pathophysiology
The Guillain-Barre syndrome is believed to be an 
autoimmune disorder based on T-cell activation with 
production of antibodies. Infectious agents such as 
Epstein-Barr virus, cytomegalovirus, mycoplasma 
pneumoniae and campylobacter jejuni, immunizations, 
surgery or parturition may trigger formation of such 
antibodies. Although most such antibodies are directed 
at myelin proteins, in some cases axonal moieties 
may be the primary target of immune-mediated nerve 
injury. Thus, while GBS is commonly known as acute 
inflammatory demyelinating polyneuropathy (AIDP), 
the primary pathologic process of this condition is axonal 
injury in many cases (i.e. in the GBS variants acute 
motor axonal neuropathy (AMAN) and acute motor and 
sensory axonal neuropathy (AMSAN)).
Specific nerve antigens have been implicated in a number 
of subtypes of GBS. The involvement of the cranial 
nerves in Miller-Fisher syndrome and polyneuritis 
cranialis, relates to development of antibodies to the 
ganglioside GQ1b, a glycolipid expressed on the 
axolemmal membrane of cranial nerves (11). Axonal 
GBS after campylobacter jejuni infection is usually 
mediated by antibodies to the GM1 ganglioside (12).
  Antibody-mediated demyelination leads to mononuclear 
infiltrates around the endoneurial vessels and vesicular 
myelin degeneration. This demyelination may be 
discrete or diffuse and may affect the peripheral nerves 
at any point from their origin in the spinal cord to the 
neuromuscular junction. The muscle weakness in GBS 
results from conduction block and concomitant or 
primary axonal injury in the affected motor nerves. Pain 
and paresthesias are the clinical correlates of sensory 
nerve involvement.
Clinical features
The major clinical features are progressive muscle 
weakness and diminished deep tendon reflexes with 
symmetric distribution. Weakness typically starts in the 
lower extremities and ascends into the upper within days 
to weeks. In a significant proportion (15-20 %) of cases, 
weakness is primarily proximal; fifty percent of affected 
children reach the nadir of weakness by one week, 80% 
by 2 weeks, and over 90% by 3 weeks. By arbitrary 
definition, all children with uncomplicated GBS will 
reach their maximum level of weakness by 4 weeks from 
onset (13). In most cases, all deep tendon reflexes are 
eventually abolished, often early in the illness (13,14). 
Occasionally the proximal reflexes can be retained and 
rarely, in otherwise typical cases, can the reflexes be 
preserved throughout the illness. Although weakness is 
the hallmark of the disease, sensory disturbances are also 
quite common, as are neuropathic pain and dysesthesia. 
Back, buttock or leg pain which is presumed to result 
from nerve root and peripheral nerve inflammation is 
the initial manifestation in about 50% of children (13). 
This pain, often poorly organized, may cause marked 
irritability and discomfort. The diagnosis of GBS should 
always be considered in small children presenting with 
pain and decreased movement or refusal to bear weight 
and when testable, position and vibratory sensations 
are diminished. The weakness, sensory loss, and pain, 
whether alone or together, often present as a gait 
disturbance with an ataxic component out of proportion 
to the muscle weakness. GBS should be considered in 
any child who has an acute gait disturbance. Some cases 
of pediatric GBS present as the Miller-Fisher variants of 
ataxia, ophthalmoplegia and areflexia without peripheral 
weakness. 
Other less common clinical features include cranial 
nerve involvement with facial weakness, difficulty in 
swallowing, and occasionally involvement of the cranial 
nerves that control ocular movements. Cranial nerve 
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involvement was observed in about 30-46% of patients 
(3,4,15). Autonomic dysfunction may occur in GBS 
accounting for some of the fatalities in the condition. 
Presentations of autonomic involvement are disturbances 
of sweating, heart rate and rhythm, blood pressure 
control, sphincter, visceral and pupillary function (16). 
Rarely are these symptoms the primary manifestations 
of childhood GBS (13).
As described above, the clinical presentation is 
remarkably variable. Therefore, the diagnostic criteria 
so far suggested for GBS, do not encompass the full 
spectrum of this disorder. It is important to note that 
diagnosis is based on consistent confirmed clinical, 
laboratory and neurophysiologic findings with exclusion 
of other diseases (table 1).
GBS has three stages, including a progressive phase 
lasting over several days to several weeks, a plateau 
phase of similar duration, and finally the recovery phase, 
over weeks to months. The major complications occur in 
the first phase which does not persist beyond 4 weeks.
There are different forms of GBS defined by their clinical 
manifestations and variable involvement of motor and 
sensory axons of peripheral nerves (table 2). The most 
common of these forms in the western population is 
AIDP. There have been some reports on the incidence 
of the AIDP and axonal types in childhood GBS. The 
incidences of documented axonal pattern, were up to 
65% in China, 40% in Japan. 30% in Argentina, 35% 
in Turkey, 31% in Pakistan , 10% in the North America 
and about 40% in Iran (15,17-22), findings that suggest 
the variable incidence of this type in childhood GBS 
among countries. The reason is still unknown; however 
different populations have different genetic backgrounds 
and different exposures to inciting pathogenesis with 
possible differences in subtypes.
The Miller-Fisher variant is characterized by ataxia, 
areflexia, and ophthalmoplegia. Some cases are limited 
to acute pandysautonomia, pure sensory loss, or regional 
(pharyngeal-cervical-brachial) weakness.
Laboratory tests
An elevated level of CSF protein without an increase 
in the number of cells, albominocytologic dissociation, 
is the cardinal laboratory finding in GBS, which was 
first described by Guillian, Barre and Strohl in 1916, 
and after whom this syndrome is named. The time 
of the measurement of the CSF protein is critical; 
approximately 50% of patients demonstrate an initial 
elevation of CSF protein if measured in the first week of 
the illness, while the majority shows an increase in this 
protein, if measured after the first  few weeks of illness. 
CSF protein normally peaks between 80 and 200 mg/
dL at some time during the illness. The constituents of 
the CSF protein are similar to those of plasma, although 
gamma globulins with oligoclonel bands may be present, 
suggesting intrathecal synthesis of immunoglobulin. The 
CSF protein is rarely above 500 mg/dL; hence higher 
levels require looking for other causes. The cell count is 
usually under 10 cells/mm³. A finding of more than 50 
cells/ mm³ suggests other possible diagnoses, as does a 
predominance of segmented neutrophils. HIV positive 
patients have elevated cells compared to HIV-negative 
patients. CSF should be analyzed before treatment with 
intravenous immunoglobulin (IVIG) which can cause 
aseptic meningitis. 
Neurophysiologic studies (nerve conduction studies 
and electromyography) are very helpful in confirming 
the clinical diagnosis, establishing prognosis and 
categorizing GBS into its various recognized subgroups. 
Peripheral nerve demyelination is reflected in slowing 
of nerve conduction, which tends to be more profound 
in younger children (13). Because these changes are 
patchy, testing of multiple nerves reveals a non-uniform 
increase in distal latencies, slowing of nerve conduction, 
conduction block, and dispersion of motor responses. 
Both severe demyelination and axonal injury cause loss 
of amplitude of motor and sensory responses. In the 
pure axonal forms of GBS, conduction velocities are 
preserved despite loss of amplitude of motor responses. 
The late responses (F and H waves) which examine both 
distal and more proximal segments of the peripheral 
nerves are often more sensitive for identification of 
mild slowing of nerve conduction. Electromyography 
reveals a loss of motor unit action potentials (decreased 
recruitment) at early phase in the illness. Changes of 
acute denervation (fibrillation potentials and positive 
sharp waves) are not usually apparent during the first 7-
10 days of the disease course. Detailed neurophysiologic 
study enables definitive diagnosis of GBS in as many as 
90% of cases during the first week of symptoms (23). 
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Changes are virtually universal by the second week of 
illness. Electrodiagnostic studies are painful and can 
technically be difficult in small children, and should 
generally be performed only by individuals having the 
expertise.
In a recent research in our center (Tabriz children’s 
hospital) of 72 children with GBS, we had 8% normal 
findings, following electrodiagnostic studies in the first 
week, although the second study yielded abnormal 
results. Therefore it is strongly recommended to perform 
a second electrodiagnostic study in such cases. In this 
study the most common electrophysiologic abnormalities 
were low amplitude CMAP (97.2%) and abnormal F-
waves (88.9%) (22).
Urgent spinal magnetic resonance imaging (MRI) 
should be undertaken in children with severe back pain, 
a sensory level or prominent sphincter dysfunction in 
order to exclude spinal cord compression. Gadolinium 
enhancement of the cauda equine and lumbar nerve roots 
have been demonstrated on spinal MRI in children with 
GBS (24). These findings are not specific to GBS and 
their sensitivity is not very well known.  Nerve biopsy is 
virtually never required for diagnosis of pediatric GBS.
Differential diagnosis
The differential diagnosis of childhood GBS includes 
spinal cord tumours and transverse myelitis. Both may 
produce a rapidly progressive paralysis, hyporeflexia, 
and back pain. Sphincter dysfunction is common with 
spinal cord lesions, but relatively rare, and usually 
transient, in GBS. Transverse myelitis may be associated 
with marked elevation of the CSF protein and significant 
CSF pleocytosis. Although neurophysiologic studies 
are usually normal in transverse myelitis, there may be 
loss of F waves corresponding with the affected spinal 
level(s).
Tick paralysis causes an ascending quadriparesis that 
may progress after tick removal. All children living in 
in endemic areas should be searched for ticks if they 
present with gait unsteadiness and progressive weakness. 
Internal and external ophthalmoplegia are common 
in tick paralysis. On nerve conduction studies, tick 
paralysis causes temperature sensitive loss of amplitude 
of the motor responses. The CSF is usually normal in 
this condition.
Childhood botulism is uncommon but should also be 
considered in the differential diagnosis of progressive 
symmetric weakness in infancy. Botulism is suggested 
by pupillary abnormalities, ophthalmoplegia and early 
constipation. Myasthenia gravis occasionally presents 
with primarily proximal weakness in childhood. 
Repetitive nerve stimulation reveals characteristic 
abnormalities in both of these disorders.
Poliomyelitis and other enteroviral infections of the 
anterior horn cell cause acute focal and asymmetric 
limb weakness, usually in association with fever and 
pain. While nerve conduction studies reflect acute 
denervation without demyelination, CSF analysis shows 
a polymorphonuclear pleocytosis . A definitive diagnosis 
is achieved by serologic testing.
Management
Children with GBS should be admitted to hospital 
at beginning of sickness for monitoring. Although 
weakness and hypotonia may be relatively mild at onset, 
the potential for sudden, sometimes fatal, respiratory or 
autonomic compromise should always be anticipated.
   Vigilant supportive therapy is vital in GBS and includes 
monitoring for respiratory and autonomic complications 
of this disorder in addition to pain management and 
prevention of complications of immobility (constipation, 
bed sores, contractures, and renal calculi). The vital signs 
and respiratory capacity should closely be monitored. 
Progression to mechanical ventilation is likely to occur 
in those patients with rapid disease progression, bulbar 
dysfunction, dysautonomia, inability to lift the elbows 
or head, vital capacity <60% and markedly attenuated 
(>80%) CMAP amplitude of the deep peroneal nerve 
(25,26). As many as 15- 20% of children require 
ventilatory support for acute GBS.
  Blood pressure liability may be prominent, especially in 
very sick children. Hypertension should be treated only 
in symptomatic and extreme cases, because there may 
be marked sensitivity to antihypertensive agents. Pacing 
devices are rarely required for children with severe 
bradycardia. Some patients with severe GBS require 
treatment for gastroparesis, ileus and urinary retention.
Pain is commonly under recognized and undertreated 
in childhood GBS. Non-steroidal anti-inflammatory 
medications and neuropathic pain relieving agents (such as 
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gabapentin, carbamazepin and tricyclic antidepressants) 
are used. Corticosteroids may be effective in alleviating 
pain. Opioid analgesics are often required for adequate 
analgesia. It is not acceptable clinical practice to let a 
child suffer pain because of concerns for the potential 
respiratory effects of narcotics.
Physiotherapy should be initiated immediately after 
control of pain in childhood GBS and continued 
throughout the recovery period. Careful attention should 
also be paid to nutritional requirements of the patient 
because inadequate caloric intake may lead to muscle 
catabolism.
Treatment
Among available specific therapeutic interventions 
aimed at mitigating the harmful effects of the disturbed 
immune reaction, at present plasma exchange and 
intravenous immunoglobulin (IVIg) represent the 
mainstay of immunomodulatory treatment of GBS. 
Both treatments have proven to have beneficial effects in 
controlled trials, favorably altering the natural course of 
the disease. In a large group controlled trial, combination 
treatment with plasma exchange followed by IVIg did 
not provide additional significant benefit (27). 
   Intravenous immunoglobulin is generally preferred for 
treatment of childhood GBS. A total dose of 2 g/kg of 
IVIg is given over 2-5 days and is generally tolerated 
well at all ages. 
Plasma exchange (PE) can be a safe and effective 
treatment of GBS for children weighing more than 10 kg. 
The  PE regimens involved exchanging approximately 
one volume, 35-45 mL/kg, on five separate occasions 
over 1 to 2 weeks. (28). 
Alternative techniques of immunoglobulin ultra filtration, 
such as CSF filtration and immunoabsorption, have been 
reported in small adult series, but have not yet been tried 
in children with GBS.
The role of corticosteroids in the treatment regime of 
GBS may have some changes in the future. In contrast 
to other autoimmune disease, steroids have no rational 
place in the treatment of GBS. However in a Dutch study 
the combination of IVIg and corticosteroids, compared 
with IVIg per se had a positive effect on early ambulation 
(29).
 Prognosis
Children with GBS have a shorter clinical course and 
more complete recovery than adult. Mortality is low, 
and if occurs due to respiratory complications and fatal 
cardiac arrhythmias. Relapses are uncommon,  and 
generally responsive to immunomodulatory treatment. 
A small percentage of children presenting with GBS 
later develop choronic inflammatory polyneuropathy 
(30, 31).  
CHILDHOOD GUILLAIN-BARRE SYNDROME  
12 Iran J Child Neurology  Jan  2009
Table 1: Definition of Guillian- Barre syndrome (modified from Asbury  and Cornblath ) 1
I.    Features required for diagnosis
       A. Progressive motor weakness of more than one limb 
       B. Areflexia or marked hyporeflexia  
II.    Features strongly supportive of the diagnosis
        A. Clinical features 
             1. Progression over days to a few weeks
             2. Relative symmetry
             3. Mild sensory symptoms or signs
             4. Cranial nerve involvement    
             5. Recovery,  usually begins 2- 4 weeks after progression stops
             6. Autonomic dysfunction 
             7. Absence of fever at onset 
        B. Laboratory abnormalities 
             1. Elevated CFS protein (>45 mg/dl)after the first week of symptoms                        
              2. Abnormal electrodiagnosis with slowed conduction or prolonged F waves 
III.  Features casting doubt on the diagnosis
        A. Marked,  persistent asymmetry of weakness
        B. Persistent bladder or bowel dysfunction
        C. Bladder or bowel dysfunction at onset
        D. More than 50 mononuclear cells/ µl in CFS (excluding HIV)
        E. Sharp sensory level
IV.  Features that rule out the diagnosis
        A. Current history of hexacarbon abuse
        B. Abnormal porphyrin metabolism
        C. Recent diphtheritic infection
        D. Evidence of polio, botulism, toxic neuropathy, organophosphates poisoning, tic paralysis  
  
Table 2: Clinical spectrum of Guillian- Barre syndrome (GBS)
Acute inflammatory demyelinating polyneuropathy (AIDP)
Acute motor axonal neuropathy (AMAN)
Acute motor and sensory axonal neuropathy (AMSAN)
Miller- Fisher syndrome (MFS)
Polyneuritis cranialis
Pharyngeal- cervical- brachial syndrome
Acute sensory neuropathy of childhood
Acute pandysautonomia
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